Ellsworth Advisors LLC Has $587,000 Stake in Bausch + Lomb Corporation $BLCO

Ellsworth Advisors LLC increased its position in Bausch + Lomb Corporation (NYSE:BLCO) by 10.0% in the first quarter, HoldingsChannel reports. The firm owned 40,516 shares of the company’s stock after acquiring an additional 3,672 shares during the period. Ellsworth Advisors LLC’s holdings in Bausch + Lomb were worth $587,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Allianz Asset Management GmbH acquired a new position in Bausch + Lomb in the 1st quarter worth approximately $4,712,000. Clearline Capital LP boosted its stake in Bausch + Lomb by 38.2% in the 1st quarter. Clearline Capital LP now owns 893,790 shares of the company’s stock worth $12,960,000 after purchasing an additional 247,149 shares during the period. Trexquant Investment LP boosted its stake in Bausch + Lomb by 5.8% in the 1st quarter. Trexquant Investment LP now owns 20,255 shares of the company’s stock worth $294,000 after purchasing an additional 1,108 shares during the period. Nexpoint Asset Management L.P. boosted its stake in Bausch + Lomb by 147.6% in the 1st quarter. Nexpoint Asset Management L.P. now owns 50,158 shares of the company’s stock worth $727,000 after purchasing an additional 29,900 shares during the period. Finally, Tabor Asset Management LP acquired a new position in Bausch + Lomb in the 1st quarter worth approximately $338,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BLCO. Morgan Stanley lifted their target price on shares of Bausch + Lomb from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Evercore ISI lifted their target price on shares of Bausch + Lomb from $15.50 to $16.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. HC Wainwright lifted their target price on shares of Bausch + Lomb from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Barclays decreased their target price on shares of Bausch + Lomb from $19.00 to $16.00 and set an “equal weight” rating for the company in a research note on Monday, June 9th. Finally, Wells Fargo & Company lifted their target price on shares of Bausch + Lomb from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $15.56.

Bausch + Lomb Trading Up 2.1%

Shares of NYSE:BLCO opened at $15.31 on Friday. The stock has a market capitalization of $5.42 billion, a PE ratio of -19.63, a P/E/G ratio of 1.53 and a beta of 0.63. Bausch + Lomb Corporation has a 1 year low of $10.45 and a 1 year high of $21.69. The firm has a fifty day moving average price of $14.30 and a 200 day moving average price of $13.44. The company has a current ratio of 1.55, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. Bausch + Lomb’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. Analysts expect that Bausch + Lomb Corporation will post 0.74 EPS for the current fiscal year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.